127 related articles for article (PubMed ID: 35123622)
1. [Evaluation of the Efficacy and Safety of Chemotherapy in Elderly Patients with Multiple Myeloma under Different Frailty Scores].
Xue R; Cheng L; Song LM; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):170-174. PubMed ID: 35123622
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
Lee HS; Kim K; Lee JJ; Yoon SS; Bang SM; Kim JS; Eom HS; Yoon DH; Lee Y; Shin HJ; Park Y; Jo JC; Lee WS; Do YR; Mun YC; Lee MH; Kim HJ; Kim SH; Kim MK; Lim SN; Park SK; Yi JH; Lee JH; Min CK;
Int J Hematol; 2021 Jan; 113(1):81-91. PubMed ID: 32889695
[TBL] [Abstract][Full Text] [Related]
3. Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study.
Efficace F; Gaidano G; Petrucci MT; Niscola P; Cottone F; Codeluppi K; Antonioli E; Tafuri A; Larocca A; Potenza L; Fozza C; Pastore D; Rigolin GM; Offidani M; Romano A; Kyriakou C; Cascavilla N; Gozzetti A; Derudas D; Vignetti M; Cavo M
Lancet Healthy Longev; 2022 Sep; 3(9):e628-e635. PubMed ID: 36102777
[TBL] [Abstract][Full Text] [Related]
4. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores.
Engelhardt M; Dold SM; Ihorst G; Zober A; Möller M; Reinhardt H; Hieke S; Schumacher M; Wäsch R
Haematologica; 2016 Sep; 101(9):1110-9. PubMed ID: 27479825
[TBL] [Abstract][Full Text] [Related]
5. Elderly patients with multiple myeloma: towards a frailty approach?
Zweegman S; Engelhardt M; Larocca A;
Curr Opin Oncol; 2017 Sep; 29(5):315-321. PubMed ID: 28763310
[TBL] [Abstract][Full Text] [Related]
6. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Auner HW; Gavriatopoulou M; Delimpasi S; Simonova M; Spicka I; Pour L; Dimopoulos MA; Kriachok I; Pylypenko H; Leleu X; Doronin V; Usenko G; Hajek R; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Stevens DA; Quach H; Jagannath S; Moreau P; Levy M; Badros A; Anderson LD; Bahlis NJ; Facon T; Mateos MV; Cavo M; Chai Y; Arazy M; Shah J; Shacham S; Kauffman MG; Richardson PG; Grosicki S
Am J Hematol; 2021 Jun; 96(6):708-718. PubMed ID: 33755235
[TBL] [Abstract][Full Text] [Related]
7. Electronic FRAIL score may predict treatment outcomes in older adults with myeloma.
Chan H; Chong YH; Seow MY; Li J; Garg P; Kelly M; Neylon A; McDiarmid B; Tan S; Jackson S
J Geriatr Oncol; 2021 May; 12(4):515-520. PubMed ID: 33046409
[TBL] [Abstract][Full Text] [Related]
8. Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population.
Lee HS; Lee J; Jo JC; Jung SH; Lee JJ; Kim D; Lee S; Song K
Sci Rep; 2021 Nov; 11(1):22907. PubMed ID: 34824362
[TBL] [Abstract][Full Text] [Related]
9. [Clinical Efficacy of Low-Dose Bortezomib-Based Triple Combination Therapy in the Treatment of Elderly Multiple Myeloma].
Chen YY; Li YH; Wang DM; Meng Z; Liu S; Guo SQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):535-539. PubMed ID: 32319392
[TBL] [Abstract][Full Text] [Related]
10. [A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].
Hao QY; Chen H; Liu KY; Wen L; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2016 Sep; 55(9):689-94. PubMed ID: 27586976
[TBL] [Abstract][Full Text] [Related]
11. Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).
Brioli A; Manz K; Pfirrmann M; Hänel M; Schwarzer AC; Prange-Krex G; Fabisch C; Knop S; Illmer T; Krammer-Steiner B; Hochhaus A; von Lilienfeld-Toal M; Mügge LO
J Cancer Res Clin Oncol; 2020 Mar; 146(3):749-759. PubMed ID: 31788741
[TBL] [Abstract][Full Text] [Related]
12. Geriatric Assessment to Predict Survival and Risk of Serious Adverse Events in Elderly Newly Diagnosed Multiple Myeloma Patients: A Multicenter Study in China.
Zhong YP; Zhang YZ; Liao AJ; Li SX; Tian C; Lu J
Chin Med J (Engl); 2017 Jan; 130(2):130-134. PubMed ID: 28091402
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma.
Facon T; Niesvizky R; Mateos MV; Siegel D; Rosenbaum C; Bringhen S; Weisel K; Ho PJ; Ludwig H; Kumar S; Wang K; Obreja M; Yang Z; Klippel Z; Mezzi K; Goldrick A; Tekle C; Dimopoulos MA
Blood Adv; 2020 Nov; 4(21):5449-5459. PubMed ID: 33166401
[TBL] [Abstract][Full Text] [Related]
14. Geriatric Assessment and Frailty Scores Predict Mortality in Myeloma: Systematic Review and Meta-analysis.
Salazar AS; Recinos LM; Mian HS; Stoll C; Simon LE; Sekhon S; Colditz GA; Wildes TM
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):488-496.e6. PubMed ID: 31133527
[TBL] [Abstract][Full Text] [Related]
15. Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years.
Belotti A; Ribolla R; Cancelli V; Crippa C; Bianchetti N; Ferrari S; Bottelli C; Cattaneo C; Tucci A; De La Fuente Barrigon C; Rossi G
Am J Hematol; 2020 Jul; 95(7):759-765. PubMed ID: 32242970
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma.
Nakazato T; Hagihara M; Sahara N; Tamai Y; Ishii R; Tamaki S; Wake A; Tajika K; Sakai R; Kobayashi T; Hua J; Inoue M; Aisa Y; Fujisawa S; Miyazaki K; Irie S; Tanaka E; Higashihara M
Ann Hematol; 2021 Nov; 100(11):2745-2754. PubMed ID: 34333665
[TBL] [Abstract][Full Text] [Related]
17. [Clinical features and prognosis of 93 elderly patients with multiple myeloma].
Chen HM; Zhou F; Wei W; Peng R; Shi HT; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):744-748. PubMed ID: 29081189
[No Abstract] [Full Text] [Related]
18. Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma to Drive Personalized Treatment Decisions.
Nathwani N; Kurtin SE; Lipe B; Mohile SG; Catamero DD; Wujcik D; Birchard K; Davis A; Dudley W; Stricker CT; Wildes TM
JCO Oncol Pract; 2020 Jan; 16(1):e92-e99. PubMed ID: 31765266
[TBL] [Abstract][Full Text] [Related]
19. Real‑life experience with bortezomib‑based regimens in elderly patients with newly diagnosed multiple myeloma and comorbidities: a Polish retrospective multicenter study.
Hus I; Walter-Croneck A; Masternak A; Jurczyszyn A; Usnarska-Zubkiewicz L; Bołkun Ł; Druzd-Sitek A; Rymko M; Łętowska J; Lech-Marańda E; Pasiarski M; Dmoszyńska A
Pol Arch Intern Med; 2017 Nov; 127(11):765-774. PubMed ID: 28906482
[TBL] [Abstract][Full Text] [Related]
20. Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older.
Murillo A; Cronin AM; Laubach JP; Hshieh TT; Tanasijevic AM; Richardson PG; Driver JA; Abel GA
J Geriatr Oncol; 2019 May; 10(3):486-489. PubMed ID: 30472368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
